Is omega-3 ‘so 2008’?

Article

 

San Diego-“The title of this course is appropriate,” said Kimberly Reed, OD, at the opening of her Ocular Nutrition Society presentation, Controversies in Nutrition. The content of Dr. Reed’s course was especially controversial in light of the AREDS 2 report that was just recently released. But the controversy didn’t end there.

Dr. Reed began her lecture with a criticism of the overly dramatic publicity resulting from a piece on omega-3 published in the September 2012 Journal of the American Medical Association (JAMA). The summaries of this research said that omega-3s are not associated with lower risk of all-cause mortality cardiac threat or stroke. However, what’s overlooked is that this was a meta-analysis, she said. It looked at 20 different studies. In other words, these are not all the same type of patient. There was a lot of variation. Too much, she said. Also, the omega dosage range was huge, varying from 0.027 g to 6 g per day. Likewise, age varied greatly, as did the end point, or points-in some studies it was death, in others it was stroke. In fact, a lot of the patients were extremely sick.

“This type of meta-analysis is of little value,” said Dr. Reed, who also questioned what types of omega-3 were used in the JAMA study. Dr. Reed pointed out that risk of sudden cardiac death was reduced by as much as 90% with omega-3s according to another study that was published in the New England Journal of Medicine. Likewise, Dr. Reed also cited a study that found a 27% reduced risk. And, she added, coronary heart disease, specifically, was reduced by 50% in a study by Mozaffarian. This long-term study watched people over 16 years, she noted. “And omega-3s added an average 2 years of life.”

“But what about AREDS 2?” she asked the audience. It used 1000 mg total omega-3 (350 DHA 650 EHA) and it didn’t have much affect in preventing progression from moderate to advanced disease. The Rotterdam study showed a 35% reduction in risk with dietary intake, she noted.

So why did this happen in AREDS 2? Is 350 DHA 650 EHA not enough? Stuart Richer, OD, PhD, nutrition science lecturer who was also presenting at the meeting, said he now recommends double and triple strength fish oils.

Regarding dose, Dr. Reed said, “for most patients 2000 of omega-3 EPA/DHA is required to surpass the 8% Red Blood Cell saturation found to be beneficial in reducing cardiovascular mortality.”ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
© 2025 MJH Life Sciences

All rights reserved.